相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Petros Pharmaceuticals' proprietary AI-integrated technology achieved success in 30 out of 31 consumer comprehension objectives, meeting FDA's thresholds for potential prescription to over-the-counter drug transitions. - The 400-patient study demonstrated strong results across critical objectives, with successful achievement of 4 out of 5 most critical objectives and all secondary objectives exceeding 84% lower bound threshold. - The technology aligns with FDA's new ACNU rules for Rx-to-OTC switches, positioning Petros as a key player in the emerging self-care pharmaceutical market.
- Petros Pharmaceuticals completed a Formative Human Factors study for its AI-integrated Web App, aimed at facilitating over-the-counter access to Stendra (avanafil) for erectile dysfunction. - The study achieved a 90% or better error-free completion rate across nearly 5,820 tasks, demonstrating the Web App's potential to guide consumers in self-selection and appropriate use. - The AI interface verified consumer identity, marking a first in Rx-to-OTC switch programs and aligning with FDA's Additional Conditions for Nonprescription Use (ACNU) regulations. - This milestone allows Petros to proceed with the next phase of its program, potentially making Stendra the first in its class to gain OTC status, pending FDA approval.
- Petros Pharmaceuticals has successfully launched an AI tool integrated into its web app for patient self-screening, aiming to optimize the safe use of Stendra. - The AI tool is being tested in a Human Factors study to assess the web app's effectiveness in guiding appropriate self-selection for Stendra use. - Petros believes the AI component addresses FDA requests for optimizing patient selection, supporting the development of Stendra as an over-the-counter (OTC) medication. - The company is pursuing increased access for Stendra, potentially making it the first erectile dysfunction medication available OTC.
